10 Cathie Wood Stocks to Buy Before the Bull Run Starts

Published August 18, 2022 at 9:14 am EDT Updated August 19, 2026 at 8:11 am EDT

In this article, we discuss 10 Cathie Wood stocks to buy before the bull run starts.

Cathie Wood, the founder and CIO of ARK Investment Management, is known as an aggressive tech bull. She makes disruptive technology and innovation her main portfolio components. On August 6, Cathie Wood discussed her views on the latest fiscal and monetary policy, addressing her audience via the ARK Invest YouTube channel. She believes that the US Inflation Reduction Act will not work to tame inflation, rather it will weaken growth and hinder productivity, citing higher taxes for corporations and Medicare and drug pricing initiatives which will cause a slowdown in healthcare and pharma.

On August 1, Cathie Wood categorically disagreed with the Fed Chairman Jerome Powell, who believes the United States is not seeing signs of a recession. Wood believes that the country is facing an inventory-led recession, with advertisers pulling back their spending “dramatically”. For example, Snap Inc. (NYSE:SNAP) and Meta Platforms, Inc. (NASDAQ:META) reported lower ad spending on their platforms lately, and Walmart Inc. (NYSE:WMT) and Target Corporation (NYSE:TGT) also said that profits will be hit due to surplus inventory.

ARK Invest bottomed a month before the Nasdaq 100 and S&P 500 posted their lows so far this year, which leads Cathie Wood to believe that her fund will rebound. Some of the Cathie Wood stocks to buy before the bull run starts include Autodesk, Inc. (NASDAQ:ADSK), UiPath Inc. (NYSE:PATH), and monday.com Ltd. (NASDAQ:MNDY).

10 Cathie Wood Stocks to Buy Before the Bull Run Starts

Cathie Wood of ARK Investment Management

Our Methodology

We used the Q2 2022 portfolio of Cathie Wood’s ARK Investment Management for this analysis, selecting the innovative stocks that Wood is bullish on. These stocks have suffered significant share price losses year to date, and hedge funds are also backing out of most of these securities in Q2. However, Cathie Wood strengthened her position in these companies as she sees long-term potential in them.

While these stocks are down in 2022, they can gain a lot of value when the bull run begins and when investors start to move towards risky tech stocks that are working on long-term projects.

10. TuSimple Holdings Inc. (NASDAQ:TSP)

Number of Hedge Fund Holders: 12

TuSimple Holdings Inc. (NASDAQ:TSP) is a California-based autonomous technology company that manufactures a portfolio of purpose-built L4 autonomous semi-trucks for the North American market. Cathie Wood has always been bullish on innovative tech stocks like TuSimple Holdings Inc., and she upped her stake by 5% in Q2 2022, holding 13.5 million shares worth $113.3 million, representing 0.65% of the total 13F securities. The stock has lost more than 76% in value year to date, however, Wood remains positive on TuSimple Holdings Inc.. The stock traded higher on August 1 after the company announced it had secured a $15 million equity investment from Rubric Capital, a New York-based hedge fund.

Baird analyst Ben Kallo on August 3 maintained an Outperform rating on TuSimple Holdings Inc. and lowered the price target on the stock to $11 from $17. The analyst observed that TuSimple Holdings Inc. made modest changes to full-year guidance and reaffirmed the revenue outlook while reducing forecast for adjusted EBITDA loss and stock-based comp expense. He said the stock will potentially be pressured, but he maintained his rating due to technology, optionality of the China business, and its cash balance.

According to Insider Monkey’s data, 12 hedge funds were long TuSimple Holdings Inc. at the end of Q2 2022, down from 17 funds in the earlier quarter. David Ma’s Composite Capital is a prominent shareholder of the company, with 9.2 million shares worth $66.7 million.

In addition to Autodesk, Inc., UiPath Inc., and monday.com Ltd., Cathie Wood boosted her stake in TuSimple Holdings Inc. during the June quarter.

9. Twist Bioscience Corporation (NASDAQ:TWST)

Number of Hedge Fund Holders: 14

Twist Bioscience Corporation (NASDAQ:TWST) is a California-based synthetic biology company that manufactures and sells synthetic DNA-based products. Twist Bioscience Corporation stock has plummeted about 41% year to date as of August 17. However, Cathie Wood in Q2 2022 strengthened her hold on the stock by 20%, and revealed holding 6.2 million shares worth $213.3 million, representing 1.26% of the total 13F securities.

On August 5, Twist Bioscience Corporation posted a revenue of $56.11 million, up 60.2% year over year, outperforming Wall Street estimates by $4.05 million. The company expects the FY 2022 revenue to be approximately $203 million, up from the prior guidance of $191 million-$199 million and a consensus of $196.39 million. Twist Bioscience Corporation forecasts gross margin to be 40%, capital expenditures to be in the range of $95 million-$100 million, and net loss to be about $250 million.

On August 8, Baird analyst Catherine Ramsey Schulte raised the price target on Twist Bioscience Corporation to $56 from $43 and kept an Outperform rating on the shares. The analyst noted that order momentum was encouraging, and management lifted 2022 guidance due to strong fundamentals. The analyst also observed that while the macro backdrop continues to evolve, its large customer base and core pricing advantages give him confidence in the future outlook.

According to Insider Monkey’s Q2 data, 14 hedge funds were bullish on Twist Bioscience Corporation, with collective stakes worth $379 million. In Q1 2022, Paul Marshall and Ian Wace’s Marshall Wace LLP held a prominent position in the company, comprising about 2 million shares worth $72 million.

Here is what Baron Funds has to say about Twist Bioscience Corporation in its Q2 2021 investor letter:

“We initiated a position in Twist Bioscience Corporation, a provider of synthetic DNA. The company’s proprietary semiconductor-based platform has driven its position as the low-cost provider of DNA for a variety of high-growth applications. These include the attractive areas of synthetic biology, liquid biopsy, and antibody discovery. Of note, the antibody business has the potential to become a source of high-margin royalty streams in the future.

As further optionality, we believe Twist has a shot at disrupting the entire digital data storage industry with DNA-based storage.”

8. Accolade, Inc. (NASDAQ:ACCD)

Number of Hedge Fund Holders: 15

Accolade, Inc. (NASDAQ:ACCD) is a Pennsylvania-based company that develops technology-led solutions so people can navigate and utilize the healthcare system and their workplace benefits in the United States. The company posted a Q2 revenue of $85.5 million, up 43.7% year over year, topping market consensus by $3.53 million. The stock has plummeted about 57% year to date. However, Cathie Wood sees potential in the company as she lifted her stake in Accolade, Inc. by 29% in Q2 2022, holding 6.25 million shares worth $40 million.

On August 11, DA Davidson analyst Robert Simmons initiated coverage of Accolade, Inc. with a Buy rating and a $16 price target. The analyst is optimistic about the company building trusted relationships with customers to achieve better outcomes in medical situations. The analyst added that Accolade, Inc. should be able to deliver its margin targets over the next few years, reaching breakeven by FY25, and ultimately seeing strong long-term profitability.

According to Insider Monkey’s data, 15 hedge funds were long Accolade, Inc. at the end of Q2 2022, compared to 22 funds in the earlier quarter. Rock Springs Capital Management is a notable shareholder of the company, with 2.20 million shares worth $16.2 million.

Here is what Baron Discovery Fund has to say about Accolade, Inc. in its Q4 2021 investor letter:

“Accolade, Inc. is a leader in providing purpose-built, technology-enabled virtual health care and personalized engagement services. Its products are designed to help employees access care and navigate/maximize their benefits with the goals of reduced health care costs and better outcomes. Shares dropped in the fourth quarter, alongside those of other high-multiple, tech-enabled, not yet profitable healthcare companies as investors became more focused on the path to profitability versus pure revenue growth and revisited valuations given the outlook for higher interest rates. Investors also grew more sensitive to perceived competition, as the healthcare IT space continues to attract significant venture capital. We continue to have a positive long-term view on this high-quality, well-managed company. We believe that Accolade has a truly differentiated offering, which is well aligned with the industry’s movement towards value-based care, and which delivers a measurable return on investment to clients. The 2021 acquisitions of 2ndMD and Plushcare, second opinion and virtual primary care providers, respectively, significantly broadened Accolades’ value proposition and should allow for meaningful cross-selling and higher-margin opportunities in 2022 and beyond. We added to our position in Accolade as we believe that shares have been oversold due to macroeconomic reasons rather than fundamental value reasons.”

7. Xometry, Inc. (NASDAQ:XMTR)

Number of Hedge Fund Holders: 16

Xometry, Inc. (NASDAQ:XMTR) is a Maryland-based company that operates a marketplace which allows buyers to access manufactured parts and assemblies in the United States and internationally. On August 10, Xometry, Inc. rallied 23% as Q2 revenue increased 89% year over year, supported by higher marketplace growth and supplier services. The company reported robust gross margin and gross profit trends driven by AI pricing, supplier selection, and additional supplier services. Cathie Wood boosted her stake in the company by 9% in Q2 2022, holding 187,952 shares worth $6.4 million. The stock has declined about 7.3% year to date as of August 17, but the gains it has recently racked up make it a top stock to purchase before the bull market starts and the price shoots up.

On August 11, CL King analyst David Silver raised the price target on Xometry, Inc. to $65 from $55 and reaffirmed a Buy rating on the shares after the company posted Q2 results that beat market estimates and raised its guidance for FY22 revenue. He sees Xometry, Inc.’s value proposition as “compelling” and called the stock “a speculative investment choice appropriate for those willing to accept high share price volatility in pursuit of well-above-market returns”.

According to Insider Monkey’s data, 16 hedge funds were bullish on Xometry, Inc. at the end of Q2 2022, compared to 19 funds in the prior quarter. Jose Fernandez’s Stepstone Group is the biggest stakeholder of the company, with 2.14 million shares worth about $73 million.

6. 10x Genomics, Inc. (NASDAQ:TXG)

Number of Hedge Fund Holders: 17

10x Genomics, Inc. (NASDAQ:TXG) was incorporated in 2012 and is headquartered in Pleasanton, California. It is a life science technology company that develops instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. While the stock has lost about 71% in value year to date as of August 17, Cathie Wood upped her stake by 7% in Q2 2022, holding 3.60 million shares worth $184.45 million, representing 1.09% of the total 13F portfolio. She has held the position since Q2 2020.

On August 10, Morgan Stanley analyst Tejas Savant maintained an Overweight rating on 10x Genomics, Inc. but lowered the price target on the stock to $70 from $100 after the company posted Q2 results in line with its pre-announcement and slashed guidance, which was “unsurprising” after the initial release. The prominent outlook reset should be “a clearing event for the stock,” said the analyst, who appreciates the setup into 2023 and beyond with Fixed RNA Profiling and CytAssist experiencing robust preliminary traction and Xenium on track for year-end.

According to Insider Monkey’s data, 17 hedge funds were bullish on 10x Genomics, Inc. at the end of June 2022, with combined stakes worth $512.6 million. In Q2 2022, SRS Investment Management was a notable position holder in the company, with 2.75 million shares worth $124.8 million.

In addition to Autodesk, Inc., UiPath Inc., and monday.com Ltd., 10x Genomics, Inc. is one of the Cathie Wood stocks to buy before the bull run starts.

Here is what ClearBridge All Cap Growth Strategy has to say about 10x Genomics, Inc. in its Q4 2021 investor letter:

“We also established a position in 10x Genomics (TXG). TXG is the dominant player in single-cell analysis and enjoys a duopoly in spatial profiling, two emerging areas of scientific research. Though the company is not yet profitable, we are attracted to the business’s strong gross margin profile and a high degree of visibility as consumables account for 85% of revenue. We also continue to see opportunities for investment in other disruptive areas of health care with large addressable markets, like diabetes.”

5. Stratasys Ltd. (NASDAQ:SSYS)

Number of Hedge Fund Holders: 21

Stratasys Ltd. (NASDAQ:SSYS) is a Minnesota-based company that provides polymer-based 3D printing solutions. Its products and services are primarily used in the aerospace, automotive, transportation, healthcare, consumer products, dental, medical, and educational industries. The stock is in line with Cathie Wood’s disruptive tech investing strategy, and in the second quarter of 2022, and her ARK portfolio held more than 8 million shares worth about $170 million, representing 0.96% of the total 13F securities. As of August 17, the stock is down about 25% year to date, which presents an attractive buying opportunity before the bull market starts. She lifted her stake by 6% in Q2 2022.

On August 16, Credit Suisse analyst Shannon Cross initiated coverage of Stratasys Ltd. with an Outperform rating and a $24 price target. The analyst observed that Stratasys Ltd. is the sole 3D printing company in Credit Suisse’s coverage with an Outperform rating, given its “strong” operational performance and specialization in polymer technologies. The analyst contended that revenue is shifting to manufacturing applications and that margins should improve with revenue.

According to Insider Monkey’s Q2 data, 21 hedge funds were bullish on Stratasys Ltd., with collective stakes worth $250 million. Renaissance Technologies held a notable stake in the company, comprising 946,432 shares worth roughly $18 million.

Here is what Alger Spectra Fund has to say about Stratasys Ltd. in its Q1 2021 investor letter:

“Short position Stratasys also contributed to performance. Stratasys is one of the larger 3D printing companies. While additive manufacturing (3D printing) is a revolutionary concept, it has only seen its primary adoption for manufacturing prototypes and test parts, not high-volume end-use parts. Unfortunately for incumbents like Stratasys, additive manufacturing has continued to attract capital and dozens of new entrants have emerged with new technologies targeting specific applications. Industry pioneers like Stratasys have seen key patents expire and have lost market share to new competition. As a result of these factors, Stratasys has not grown for five years. Some industry participants believe that Stratasys’ plastic extrusion technology is simply too slow to be an acceptable solution for higher volume manufacturing. The short position contributed to portfolio returns when Stratasys’ shares declined due to year-over-year revenue contraction, continuing market share losses, a talent exodus, the issuance of new shares via a secondary offering, and no significant progress on developing new opportunities in promising additive verticals like metal and dental.”

4. UiPath Inc. (NYSE:PATH)

Number of Hedge Fund Holders: 24

UiPath Inc. is a New York-based company that offers an end-to-end automation platform with a range of robotic process automation solutions. UiPath Inc. stock has plunged more than 55% year to date as of August 17. Cathie Wood boosted her stake in UiPath Inc. by 12% in Q2 2022, holding 37.6 million shares worth $641.75 million, representing 3.79% of the total 13F holdings.

Canaccord analyst Kingsley Crane on July 7 initiated coverage of UiPath Inc. with a Buy rating and a $25 price target. He is bullish on UiPath Inc.’s ability to leverage automation in a large set of use cases and expects partners like EY and PwC to lend it “critical sales leverage,” the analyst told investors.

According to Insider Monkey’s Q2 data, 24 hedge funds were bullish on UiPath Inc., with combined stakes worth $1.26 billion. Alkeon Capital Management held a sizable stake in the company, comprising 15.4 million shares valued at $281.6 million.

Here is what ClearBridge Investments has to say about UiPath Inc. in its Q2 2021 investor letter:

“We participated in the IPO of UiPath, a developer of software for robotic process automation that uses AI, natural language processing and design to streamline complex processes across a variety of technology environments. The company is an industry leader with a superior solution for leveraging software to optimize workloads. Organizations around the world are beginning to understand the power of automation, with momentum picking up toward fully automating business processes, a $60 billion market today that could grow to $200 billion or more by 2030. UiPath has a unique pricing model, broad partner ecosystem and thoughtful management team supporting one of the strongest growth profiles in technology. Risks we are watching include a partial cloud transition ahead and increased competition from larger software platforms over time.”

3. monday.com Ltd. (NASDAQ:MNDY)

Number of Hedge Fund Holders: 25

monday.com Ltd. is an Israel-based developer of work management software applications in the United States, Europe, the Middle East, Africa, and internationally. The stock has lost 57% in value year to date as of August 17. However, Cathie Wood strengthened her position in the stock by 14% in Q2 2022, holding 236,624 shares worth $26.8 million. On August 8, monday.com Ltd. released its full-year guidance, which sparked a rally in cloud stocks. The company expects sales to be between $498 million and $502 million, up from the earlier outlook of $488 million to $492 million and compared to Wall Street consensus of $491.3 million.

On August 9, DA Davidson analyst Robert Simmons raised the price target on monday.com Ltd. to $175 from $145 and kept a Buy rating on the shares. The company’s Q2 results exceeded investor expectations and alleviated fears of stronger macro headwinds or customer downgrades, the analyst told investors. The analyst added that despite forex headwinds and weakness in Europe, monday.com Ltd.’s growth remains impressive as it scales.

Among the hedge funds tracked by Insider Monkey, 25 funds were bullish on monday.com Ltd. at the end of Q2 2022, compared to 24 funds in the last quarter. Chase Coleman’s Tiger Global Management is the leading stakeholder of the company, with 778,126 shares worth $80.3 million.

2. InMode Ltd. (NASDAQ:INMD)

Number of Hedge Fund Holders: 27

InMode Ltd. (NASDAQ:INMD) is an Israeli company that develops minimally invasive aesthetic medical products for women’s health conditions and procedures in the United States and internationally. Cathie Wood increased her stake in InMode Ltd. by 29% in Q2 2022, holding 73,637 shares worth about $2 million. On July 28, the company reported its Q2 results, posting earnings per share of $0.59 and a revenue of $113.55 million, topping market consensus by $0.08 and $10.55 million, respectively.

Baird analyst Jeff Johnson on July 29 raised the price target on InMode Ltd. to $53 from $44 and kept an Outperform rating on the shares.

According to Insider Monkey’s data, 27 hedge funds were long InMode Ltd. at the end of June 2022, compared to 34 funds in the prior quarter. Jim Simons’ Renaissance Technologies is the leading position holder in the company, with 3.10 million shares worth about $69.5 million.

Here is what Alger has to say about InMode Ltd. in its Q3 2021 investor letter:

“InMode Ltd. was among the top contributors to performance. InMode designs, develops, manufactures and commercializes innovative minimally invasive and non-invasive aesthetic medical products. InMode’s platforms harness novel radio frequency (RF) technology to enable emerging minimally invasive procedures that bridge the gap between temporary treatments like facials and more invasive surgical procedures like facelifts across several categories of surgical specialties such as plastic surgery, gynecology, dermatology, ophthalmology and otolaryngology (ear, nose and throat care).

The aesthetics market is seeing strong tailwinds coming out of the Covid-19 pandemic. These tailwinds include the “Zoom effect,” or dissatisfaction with one’s personal appearance after viewing one’s own face on Zoom, which has resulted in more people deciding to undergo aesthetic procedures. De-stigmatization of aesthetics procedures, aided by social media platforms, is also supportive of InMode’s results. Between the strong growth of its existing product lines and the anticipated launch of two new products, investors perceive InMode as being well positioned to capitalize on the broader strength of the aesthetics market, which is a key reason shares outperformed in the third quarter.”

1. Autodesk, Inc. (NASDAQ:ADSK)

Number of Hedge Fund Holders: 53

Autodesk, Inc. is a California-based company involved in providing 3D design, engineering, and entertainment software and services worldwide. Cathie Wood’s ARK Investment Management added 5% to its prior Autodesk, Inc. position in Q2 2022, holding 44,254 shares worth more than $9 million. Cathie Wood has been bullish on Autodesk, Inc. since 2018, and the stock has plunged about 20% year to date, which presents an attractive buying opportunity before the bull run starts.

Mizuho analyst Gregg Moskowitz on August 17 raised the price target on Autodesk, Inc. to $290 from $250 and maintained a Buy rating on the shares. After an extended sell-off, software and the broader market have notably rallied in the last weeks, the analyst told investors. The analyst has “picked up more indications of softening enterprise software demand, albeit not anything reflective of a material change”. He thinks software valuations remain attractive.

According to Insider Monkey’s data, 53 hedge funds were bullish on Autodesk, Inc. at the end of June 2022, up from 50 funds in the earlier quarter. Ian Simm’s Impax Asset Management is the leading position holder in the company, with 1.2 million shares worth $221.2 million.

Here is what Polen Global Growth has to say about Autodesk, Inc. in its Q4 2021 investor letter:

“We added to Autodesk on share price weakness. Near-term concerns have made the valuations of the company quite attractive in our view. Autodesk has consistently reported solid results, but management recently provided lower than expected guidance, noting supply chain issues, inflation squeezing its customer margins, global labor shortages, and complications from rolling and unpredictable COVID lockdowns globally. In aggregate, these issues mean that fewer client projects have been completed, despite high endmarket demand. Ultimately, many of these productivity pressures will likely drive the need to digitize further.

To be clear, much of the pressure on Autodesk’s share price recently was due to expectations, not a decline in the fundamentals of the business. The company continues to grow revenues at greater than mid-teens rates while simultaneously enjoying record renewal rates. While each of the noted factors present real challenges in the near term, we think the lower share price provides long-term investors an opportunity. Given the secular trend towards digitization and the ever-increasing mission-critical nature of Autodesk’s products, we are confident in the long-term investment case.”

You can also take a look at 10 Best Stocks To Buy Now According to Billionaire Marc Lasry’s Avenue Capital and 7 Energy Stocks to Buy Now According to Billionaire Leon Cooperman.

Follow Insider Monkey on Twitter